AYOXXA Trademark

Trademark Overview


On Friday, October 6, 2017, a trademark application was filed for AYOXXA with the United States Patent and Trademark Office. The USPTO has given the AYOXXA trademark a serial number of 79224525. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, October 10, 2025. This trademark is owned by AyoxxA Biosystems GmbH. The AYOXXA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; veterinary pharmaceutical preparations for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations; diagnostic agents for medical purposes; diagnostic agents for veterinary purposes; chemical and biochemical preparations for medical purposes, namely, for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-in...
ayoxxa

General Information


Serial Number79224525
Word MarkAYOXXA
Filing DateFriday, October 6, 2017
Status709 - CANCELLED - SECTION 71
Status DateFriday, October 10, 2025
Registration Number5705785
Registration DateTuesday, March 26, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 8, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; veterinary pharmaceutical preparations for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations; diagnostic agents for medical purposes; diagnostic agents for veterinary purposes; chemical and biochemical preparations for medical purposes, namely, for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; chemical and biochemical reagents for medical purposes; chemical and biochemical preparations for veterinary purposes, namely, for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations; chemical and biochemical reagents for veterinary purposes; chemical and biochemical preparations for pharmaceutical purposes, namely, for treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases; chemical and biochemical reagents for medical or veterinary pharmaceutical purposes; biological agents for laboratory analyses for medical purposes, namely, peptides, proteins and nucleic acids used as diagnostic agents for medical purposes; biological agents for laboratory analyses for veterinary purposes, namely, peptides, proteins and nucleic acids used as diagnostic agents for veterinary purposes; chemical and biochemical preparations and reagents for medical purposes, namely, for use in DNA analyses; chemical and biochemical preparations for blood tests for medical purposes; chemical and biochemical reagents for blood tests for medical purposes; chemical and biochemical preparations for blood tests for veterinary purposes; chemical and biochemical reagents for blood tests for veterinary purposes; peptides, proteins, nucleic acids and other biomolecules, or complexes of these molecules, for medical purposes, namely, synthetic or natural peptides, proteins, allergens, metabolites or nucleic acids for the treatment and prevention of cancer, treatment and prevention of inflammatory diseases, treatment and prevention of autoimmune diseases, treatment and prevention of cardiovascular diseases, treatment and prevention of ophthalmic diseases, treatment and prevention of gastro-intestinal diseases, and treatment and prevention of neurologic diseases, protein arrays for medical diagnosis purposes, nucleic acid sequences for medical diagnosis purposes; proteins, nucleic acids and other biomolecules, or complexes of these molecules, for veterinary purposes, namely, synthetic or natural peptides, proteins, allergens, metabolites or nucleic acids for treatment of gastro-intestinal diseases, treatment of inflammatory diseases, treatment of ophthalmic diseases, and treatment of mucosa irritations in animals, protein arrays for veterinary diagnosis purposes, nucleic acid sequences for veterinary diagnosis purposes; chemical and biochemical preparations and reagents for labelling of molecules for medical detection and monitoring purposes; chemical and biochemical preparations and reagents for labelling of molecules for veterinary detection and monitoring purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, October 10, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAyoxxA Biosystems GmbH
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDE

Party NameAyoxxA Biosystems GmbH
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDE

Party NameAyoxxA Biosystems GmbH
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDE

Trademark Events


Event DateEvent Description
Wednesday, February 7, 2018NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, January 4, 2018SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, January 10, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 16, 2018APPLICATION FILING RECEIPT MAILED
Tuesday, January 16, 2018ASSIGNED TO EXAMINER
Tuesday, February 6, 2018NON-FINAL ACTION WRITTEN
Friday, February 16, 2018NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Wednesday, March 21, 2018NON-FINAL ACTION WRITTEN
Thursday, March 22, 2018NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, March 22, 2018REFUSAL PROCESSED BY MPU
Thursday, March 22, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, April 6, 2018REFUSAL PROCESSED BY IB
Monday, October 22, 2018ASSIGNED TO EXAMINER
Wednesday, November 14, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 8, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 26, 2019REGISTERED-PRINCIPAL REGISTER
Wednesday, June 26, 2019FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, July 25, 2019FINAL DISPOSITION PROCESSED
Thursday, July 25, 2019FINAL DISPOSITION NOTICE SENT TO IB
Friday, August 16, 2019FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, November 1, 2019NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, March 26, 2024COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, October 10, 2025CANCELLED SECTION 71
Tuesday, January 8, 2019PUBLISHED FOR OPPOSITION
Friday, September 21, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 21, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 21, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 19, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED